Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer

BACKGROUND: Based on promising phase II data, the histone deacetylase inhibitor entinostat is in phase III trials for patients with metastatic estrogen receptor-positive breast cancer. Predictors of sensitivity and resistance, however, remain unknown. METHODS: A total of eight cell lines and nine mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanioka, Maki, Mott, Kevin R., Hollern, Daniel P., Fan, Cheng, Darr, David B., Perou, Charles M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267061/
https://www.ncbi.nlm.nih.gov/pubmed/30497520
http://dx.doi.org/10.1186/s13073-018-0597-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267061/
https://www.ncbi.nlm.nih.gov/pubmed/30497520
http://dx.doi.org/10.1186/s13073-018-0597-3

Ejemplares similares